Samsung Bioepis

Showing 15 posts of 22 posts found.


Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars

December 2, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma

Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …


Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal

November 7, 2019
Sales and Marketing Biogen, Samsung Bioepis, pharma

Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …


Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US

July 24, 2019
Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …


FDA approves third Herceptin biosimilar with Samsung Bioepis’ Ontruzant

January 22, 2019
Manufacturing and Production, Sales and Marketing FDA, Herceptin, Samsung Bioepis, biosimilar, pharma

Samsung Bioepis’ has announced that the FDA has chosen to approve Ontruzant (trastuzumab-dttb), its biosimilar version of Roche’s Herceptin (trastuzumab), …


MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

October 15, 2018
Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …


MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

October 8, 2018
Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …


Samsung BioLogics’ shares down $6bn after accounting furore

May 2, 2018
Research and Development, Sales and Marketing Samsung BioLogics, Samsung Bioepis, biotech, drugs, pharma, pharmaceutical, south korea

Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a notice of suspected breach of …


Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

April 6, 2018
Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …


Ontruzant launches to become first Herceptin biosimilar available in the UK

March 8, 2018
Sales and Marketing Cancer, Herceptin, MSD, Ontruzant, Roche, Samsung Bioepis, pharma

Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in …


Samsung Bioepis’ Ontruzant becomes first Herceptin biosimilar approved in Europe

November 20, 2017
Sales and Marketing EMA, Herceptin, Roche, Samsung Bioepis

Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe …


Samsung completes hat-trick of big biosimilar approvals

August 25, 2017
Medical Communications, Sales and Marketing Biogen, Samsung Bioepis, biosimilars, biotech, drugs, pharma, pharmaceutical

Samsung Bioepis has announced that it, alongside its partner Biogen, has secured European Commission approval for its biosimilar version of …

Samsung Bioepis collaborates to make inroads into original drugs

August 21, 2017
Research and Development, Sales and Marketing Samsung Bioepis, Takeda, biotech, drugs, pharma, pharmaceutical

Thus far, Samsung Bioepis has made its name by being a thorn in the side of the producers of original …

Humira set to face new European biosimilar rival

June 26, 2017
Sales and Marketing CHMP, EMA, Samsung Bioepis

A position opinion from the EMA for Samsung Bioepis’ biosimilar of Humira looks set to unleash a second rival to …


J&J launches lawsuit to block release of Remicade biosimilar

May 19, 2017
Medical Communications, Sales and Marketing J&J, JJ, Remicade, Samsung Bioepis

Samsung Bioepis gained approval to launch its biosimilar to Johnson & Johnson’s Remicade just last month, on 21 April, but …


UK High Court rules against AbbVie’s Humira patents

March 6, 2017
Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar

The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …

Latest content